Related references
Note: Only part of the references are listed.Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis
Kenjiro Aogi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Jeffrey Crawford et al.
SUPPORTIVE CARE IN CANCER (2020)
Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer
Hisanaga Nomura et al.
SUPPORTIVE CARE IN CANCER (2020)
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Liang-Kung Chen et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2020)
Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer
Tarje Onsoien Halvorsen et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)
Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus
Yukinori Yamagata et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients
Sophie Kurk et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Yuko Kitagawa et al.
ESOPHAGUS (2019)
Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy
Naoki Kamitani et al.
SURGERY TODAY (2019)
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil
Yu Ohkura et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer
Takaomi Hagi et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study
Takeshi Ishikawa et al.
CANCER SCIENCE (2019)
Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer
Louise E. Daly et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2018)
Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score
Theis Aagaard et al.
JNCI CANCER SPECTRUM (2018)
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer
Grant R. Williams et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)
M. Yamasaki et al.
ANNALS OF ONCOLOGY (2017)
Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy
Shlomit Strulov Shachar et al.
CLINICAL CANCER RESEARCH (2017)
Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity
Yoshitaka Saito et al.
SUPPORTIVE CARE IN CANCER (2017)
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer
Hiroshi Miyata et al.
ANTICANCER RESEARCH (2017)
The Prevalence of Overall and Initial Lymph Node Metastases in Clinical T1N0 Thoracic Esophageal Cancer From the Results of JCOG0502, a Prospective Multicenter Study
Yasunori Akutsu et al.
ANNALS OF SURGERY (2016)
Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults
Yuhei Hamaguchi et al.
NUTRITION (2016)
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Stahl et al.
ANNALS OF ONCOLOGY (2013)
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma
Hiroki Hara et al.
CANCER SCIENCE (2013)
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer
Rabbie K. Hanna et al.
GYNECOLOGIC ONCOLOGY (2013)
A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
Nobutoshi Ando et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Surgery in Esophageal and Gastric Cancer Patients: What is the Role for Nutrition Support in your Daily Practice?
Christophe Mariette et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus
Makoto Yamasaki et al.
ONCOLOGY (2011)
Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma
Tsuneaki Hirakawa et al.
ANNALS OF HEMATOLOGY (2010)
Phase I/II Study of Docetaxel/Cisplatin/Fluorouracil Combination Chemotherapy Against Metastatic Esophageal Squamous Cell Carcinoma
Hiroaki Takahashi et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan
Meng-Yueh Chien et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2008)
Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP
A. Bosly et al.
ANNALS OF HEMATOLOGY (2008)
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity
Carla M. M. Prado et al.
CLINICAL CANCER RESEARCH (2007)
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quantification of lean bodyweight
S Janmahasatian et al.
CLINICAL PHARMACOKINETICS (2005)
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma
GH Lyman et al.
CANCER (2003)
Relationships between body composition parameters and fluorouracil pharmacokinetics
M Gusella et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Estimation of skeletal muscle mass by bioelectrical impedance analysis
I Janssen et al.
JOURNAL OF APPLIED PHYSIOLOGY (2000)